Format

Send to

Choose Destination
See comment in PubMed Commons below
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1873-6. doi: 10.1161/ATVBAHA.110.207696. Epub 2010 Jun 24.

Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.

Author information

1
Department of Medicine, Division of Cardiology, Pritzker School of Medicine, The University of Chicago, 515 N State St, Ste 2700, Chicago, IL 60654, USA. mdavidson@radiantresearch.com

Abstract

OBJECTIVE:

To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride.

METHODS AND RESULTS:

The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study.

CONCLUSIONS:

There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus.

PMID:
20576945
PMCID:
PMC2945383
DOI:
10.1161/ATVBAHA.110.207696
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center